Patents by Inventor John Michael Ketcham

John Michael Ketcham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210317134
    Abstract: Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.
    Type: Application
    Filed: March 5, 2020
    Publication date: October 14, 2021
    Inventors: Jacob Bradley Schwarz, John Michael Ketcham, Maureen Kay Reilly, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, David Juergen Wustrow, Emily Karbarz, Xinping Han, Grant Shibuya, Jack Maung, Maksim Osipov
  • Patent number: 11091495
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: August 17, 2021
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20210230168
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 29, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • Publication number: 20210188857
    Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Matthew Arnold Marx, John Michael Ketcham, Christopher Ronald Smith, John David Lawson, Aaron Craig Burns, Xiaolun Wang, Svitlana Kulyk, Anthony Ivetac
  • Publication number: 20210101904
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • Publication number: 20210079003
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • Publication number: 20210078994
    Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Inventors: Thomas P. Bobinski, Christopher Ronald Smith, Matthew Arnold Marx, John Michael Ketcham, Aaron Craig Burns, John David Lawson, Svitlana Kulyk, Jon Kuehler, Anthony Ivetac
  • Publication number: 20210032252
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 4, 2021
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Publication number: 20200339539
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Application
    Filed: April 27, 2020
    Publication date: October 29, 2020
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • Publication number: 20200325117
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Application
    Filed: April 27, 2020
    Publication date: October 15, 2020
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • Publication number: 20200308170
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • Publication number: 20200262837
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • Publication number: 20200239480
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.
    Type: Application
    Filed: January 28, 2020
    Publication date: July 30, 2020
    Inventors: Hilary Plake Beck, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, John Michael Ketcham, Jay Patrick Powers, Maureen Kay Reilly, Omar Robles-Resendiz, Hunter Paul Shunatona, James Ross Walker, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky, Jeffrey J. Jackson
  • Patent number: 10722514
    Abstract: Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 28, 2020
    Assignee: RAPT THERAPEUTICS, INC.
    Inventors: Berenger Biannic, Xinping Han, Dennis X. Hu, John Michael Ketcham, Paul Robert Leger, Jack Maung, Akinori Okano, Jacob Bradley Schwarz, Grant Shibuya, David Juergen Wustrow, Kyle Young
  • Patent number: 10683280
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: June 16, 2020
    Assignee: RAPT THERAPEUTICS, INC.
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • Patent number: 10647715
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 12, 2020
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • Patent number: 10604526
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 31, 2020
    Assignee: RAPT THERAPEUTICS, INC.
    Inventors: Hilary Plake Beck, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, John Michael Ketcham, Jay Patrick Powers, Maureen Kay Reilly, Omar Robles-Resendiz, Hunter Paul Shunatona, James Ross Walker, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky, Jeffrey J. Jackson
  • Publication number: 20190270743
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Matthew Arnold Marx, Thomas P. Bobinski, Aaron Craig Burns, John Gaudino, Julia Haas, John Michael Ketcham, John David Lawson, Brad Newhouse, Spencer Pajk, Christopher Ronald Smith, Tony P. Tang
  • Publication number: 20190233397
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.
    Type: Application
    Filed: January 24, 2019
    Publication date: August 1, 2019
    Inventors: Jeffrey J. Jackson, John Michael Ketcham, Akinori Okano, Maureen Kay Reilly, Omar Robles-Resendiz, Jacob Bradley Schwarz, Parcharee Tivitmahaisoon, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky
  • Publication number: 20190152978
    Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 23, 2019
    Inventors: Hilary Plake Beck, Berenger Biannic, Minna Hue Thanh Bui, Dennis X. Hu, John Michael Ketcham, Jay Patrick Powers, Maureen Kay Reilly, Omar Robles-Resendiz, Hunter Paul Shunatona, James Ross Walker, David Juergen Wustrow, Ashkaan Younai, Mikhail Zibinsky, Jeffrey J. Jackson